Last checked at 
LONDON (Alliance News) - ValiRx PLC said Monday that its phase I/II trial of developmental prostate cancer treatment VAL201 is progressing as announced and on schedule with its plan.
The life sciences company has made full details of the trial available on the US National Institutes of Health searchable database as is legally required immediately before application of the trial substance to human beings.
Preliminary outcomes from the first cohort of the trial are expected in the first quarter of 2015.
Shares in ValiRx are trading up 8.6% at 0.380 pence Monday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.